GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Cash Conversion Cycle

Strongbridge Biopharma (Strongbridge Biopharma) Cash Conversion Cycle : -387.48 (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Strongbridge Biopharma's Days Sales Outstanding for the three months ended in Jun. 2021 was 29.2.
Strongbridge Biopharma's Days Inventory for the three months ended in Jun. 2021 was 205.95.
Strongbridge Biopharma's Days Payable for the three months ended in Jun. 2021 was 622.63.
Therefore, Strongbridge Biopharma's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2021 was -387.48.


Strongbridge Biopharma Cash Conversion Cycle Historical Data

The historical data trend for Strongbridge Biopharma's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Cash Conversion Cycle Chart

Strongbridge Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash Conversion Cycle
Get a 7-Day Free Trial - -79.64 125.26 100.91 -111.52

Strongbridge Biopharma Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -499.39 -91.90 -56.36 -536.63 -387.48

Competitive Comparison of Strongbridge Biopharma's Cash Conversion Cycle

For the Biotechnology subindustry, Strongbridge Biopharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strongbridge Biopharma's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Cash Conversion Cycle falls into.



Strongbridge Biopharma Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Strongbridge Biopharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2020 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=30.23+255.43-397.18
=-111.52

Strongbridge Biopharma's Cash Conversion Cycle for the quarter that ended in Jun. 2021 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=29.2+205.95-622.63
=-387.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strongbridge Biopharma  (NAS:SBBP) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Strongbridge Biopharma Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Executives
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c. 10 percent owner C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner 10 percent owner C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp 10 percent owner 731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson director, officer: Chief Executive Officer DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen director 60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger director 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long officer: Chief Legal Officer C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen officer: Chief Medical Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit officer: Chief Commercial Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz officer: Chief Financial Officer 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender officer: Chief Operating Officer C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Strongbridge Biopharma (Strongbridge Biopharma) Headlines

From GuruFocus